Preview

Медицинский Совет

Расширенный поиск

Терапия постинсультных когнитивных нарушений

https://doi.org/10.21518/2079-701X-2016-17-38-41

Полный текст:

Аннотация

В статье рассмотрены основные вопросы этиологии и патогенеза постинсультных сосудистых когнитивных нарушений. Представлены исторические этапы формирования концепции постинсультной деменции. Обсуждены подходы к профилактике и терапевтической коррекции постинсультных когнитивных нарушений. Рассмотрены возможности нейротрофической терапии на примере цитиколина. 

Об авторе

А. Ю. Емелин
Военно-медицинская академия им. С.М. Кирова, Санкт-Петербург
Россия
д.м.н.


Список литературы

1. Ferri C et al. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366(9503): 2112-2117.

2. Iemolo F et al. Pathophysiology of vascular dementia. Immun Ageing, 2009, 6: 13.

3. Емелин А.Ю. Когнитивные нарушения при цереброваскулярной болезни. Неврология. Нейропсихиатрия. Психосоматика, 2014, 4: 11-18.

4. Jellinger K. Morphologic diagnosis of «vascular dementia» – a critical update. J. Neurol. Sci., 2008, 270(1–2): 1-12.

5. Tomlinson B, Blessed G, Roth M. Observations on the brains of demented old people. J. Neurol. Sci., 1970, 11(3): 205-242.

6. Hachinski V, Lassen N, Marshall J. Multi-infarct dementia. A case of mental deterioration in the elderly. Lancet, 1974, 2(7874): 207-210.

7. Tatemichi T et al. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J. neurol. neurosurg. psychiatry, 1994, 57(2): 202-207.

8. Gorelick P et al. Risk factors for dementia associated with multiple cerebral infarcts: a case– control analysis in predominantly African– American hospital–based patients. Arch. Neurol., 1993, 50(7): 714-720.

9. Ivan C et al. Dementia after stroke. The Framing ham Study. Stroke, 2004, 35(6): 1264-1268.

10. Censori B et al. Dementia after first stroke. Stroke, 1996, 27(7): 1205-1210.

11. Pohjasvaara T et al. Dementia three months after stroke: baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke, 1997, 28(4): 785-792.

12. Leys D et al. Poststroke dementia. Neurology, 2005, 4(Is.11): 752-759.

13. Breteler M еt al. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ, 1994, 308(6944): 1604-1608.

14. Altieri M et al. Delayed poststroke dementia A 4-year follow-up study. Neurology, 2004, 62: 2193-2197.

15. Емелин А.Ю. и др. Постинсультные расстройства когнитивных функций (клинико-нейровизуализационное исследование). Неврология. Нейропсихиатрия. Психосоматика, Специ- альный выпуск: Инсульт, 2013, 2: 9-15.

16. Hénon H et al. Poststroke dementia. Incidence and relationship to prestroke cognitive decline / H. Hénon. Neurology, 2001, 57(7): 1216-1222.

17. Abbott R et al. Walking and dementia in physically capable elderly men. JAMA, 2004, 292(12): 1447-1453.

18. Chan A et al. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am. J. Alzheimers Dis. Other Demen.,– 2008, 23(6): 571-85.

19. Scrameas N et al. Mediterranean diet and risk for Alzheimer`s disease. Ann. Neurol., 2006, 59(6): 877-879.

20. Forette F et al. Prevention of dementia in randomised double–blind placebo–controlled Systolic Hypertension in Europe (Syst–Eur) trial. Lancet, 1998, 352: 1347-1351.

21. Tzourio C et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med., 2003, 163(9): 1069-1075.

22. Erkinjuntti T et al. Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment. Stroke, 2004, 35: 1010.

23. Mellon L et al.Cognitive impairment six months after ischaemic stroke: a profile from the ASPIRE-S study. BMC Neurol., 2015, 15(1): 288.

24. Winblad B et al. Therapeutic use of nicergoline. Clin Drug Investig, 2008, 28(9): 533-52.

25. Pantoni, L. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J Neurol Sci., 2004, 226(1–2): 67-70.

26. Le Bars P et al. A placebo–controlled, double– blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA, 1997, 278: 1327-1332.

27. Wilkinson D et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology, 2003, 61(4): 479-86.

28. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev, 2006, 25(1): CD004746.

29. Ballard C et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr. Med. Res Opin., 2008, 9: 2561-74.

30. Orgogozo J-M et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke, 2002, 33: 1834-1839.

31. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev, 2005, 18(2): CD000269.

32. Grieb P. Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues. CNS Drugs, 2014, 28(3): 185-193.

33. Secades J, Lorenzo J. Citicoline: pharmacological and clinical review, 2006 update. Methods Find. Exp. Clin. Pharmacol., 2006, 28(Suppl. B): 1-56.

34. Conant R, Schauss AG. Therapeutic Applications of Citicoline for Stroke and Cognitive Dysfunction in the Elderly: A Review of the Literature. Alternative Medicine Review, 2004, 9(1): 17-31.

35. Overgaard K. The Effects of Citicoline on Acute Ischemic Stroke: A Review. Journal of Stroke and Cerebrovascular Diseases, 2014, 23(7): 1764-1769.

36. Amenta F, Tullio MDi, Tomassoni D.The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin. Exp. Hypertens., 2002, 24: 697-713.

37. Alvarez-Sabin J, Roman G. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke, 2011, 42(Suppl. 1): 40-3.

38. Alvarez X et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol, 1999, 9: 633-44.

39. Clark W et al. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology, 1997, 49: 671-8.

40. Dаvalos A. et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke, 2002, 33: 2850-7.

41. Парфенов В.А., Фатеева Т.Г., Косивцова О.В. Клинический опыт применения Цераксона при ишемическом инсульте. Неврология. Нейропсихиатрия. Психосоматика, 2010, 3: 67-70.

42. Dávalos A et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet, 2012, 380(9839): 349-57.

43. Cotroneo A et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin. Interv. Aging., 2013, 8: 131-137.


Для цитирования:


Емелин А.Ю. Терапия постинсультных когнитивных нарушений. Медицинский Совет. 2016;(17):38-41. https://doi.org/10.21518/2079-701X-2016-17-38-41

For citation:


Emelin A.Y. Therapy of poststroke cognitive impairment. Medical Council. 2016;(17):38-41. (In Russ.) https://doi.org/10.21518/2079-701X-2016-17-38-41

Просмотров: 280


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)